Impact of increased adiposity on extended aromatase inhibitor treatment in postmenopausal patients with ER+ breast cancer

Dr Edoardo Isnaldi and François Richard, both working at the Laboratory of Translational Breast Cancer Research at the KULeuven, presented their poster on the impact of increased adiposity on extended aromatase inhibitor treatment in postmenopausal patients with ER+ breast cancer. This study was a retrospective analysis of the SOLE trial in which after 4-6 years of adjuvant endocrine therapy, patients were randomised between continuous letrozole over 5 years versus intermittent letrozole over the same period.